<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435341</url>
  </required_header>
  <id_info>
    <org_study_id>NDS-AML-001</org_study_id>
    <secondary_id>U1111-1207-6661</secondary_id>
    <nct_id>NCT03435341</nct_id>
  </id_info>
  <brief_title>Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain</brief_title>
  <official_title>Prospective Observational Study on Overall Survival and Quality of Life in Patients Older Than 60 Years With Acute Myeloid Leukemia Diagnosis in Spain, Treated According to Standard Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the
      survival and the quality of life, the clinical management strategies and the prognostic
      factors for survival related to the patient, in a prospective cohort of patients over 60 with
      AML diagnosis in Spain and treated outside of clinical trials; that is, under conditions of
      standard clinical practice.

      The study will last 24 months in total from the inclusion of the first patient until the end
      of the last patient's follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the baseline enrolment visit, the following data corresponding to the patient's
      visits scheduled according to routine clinical practice will be collected in accordance with
      the following model:

        1. Recruitment period: One year of recruitment period, data collection at the baseline
           visit, every 3 months in one year (month 3, 6, 9 and 12).

        2. Follow-up period: data collection at the baseline visit, every 3 months in one year
           (month 3, 6, 9 and 12).

      The patient clinical history and the studyÂ´s questionnaires will be the source documents. The
      study will be carried out in the facilities of the Hematology and Hemotherapy Services of the
      participating centers, collecting the conditions of medical action according to the standard
      clinical practice.

      Being an observational study, no intervention out of standard clinical practice will be
      performed. No additional diagnostic or treatment procedures will be applied for the patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The median survival time in adult patients over 60 with AML diagnosis</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The overall survival will be calculated, defined as the time from the diagnosis date to the death date from any reason. In patients who have not died (censored) at the time of data collection, it will be considered the available time to the last control (or last date). The overall survival will be analyzed using the Kaplan-Meier method, providing the median at 95% CI. Patients who undergo a hematopoietic transplant will be censored at that time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The Kaplan Meier curve, with the median and the lower and upper limits of the 95% confidence interval, will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the socio-demographic and clinical characteristics of patients</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>A description of the study socio-demographic and clinical variables will be made. The distributions of absolute and relative frequencies of the qualitative variables will be reported, as well as the measures of central and dispersion tendency of the quantitative variables. A 95% CIs will be obtained for the main variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the disease characteristics</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>A description of the variables that characterize the disease under study will be made. The distributions of absolute and relative frequencies of the qualitative variables will be reported, as the measures of central tendency and dispersion of the quantitative variables. A 95% CIs will be obtained for the main variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the front-line treatment strategies</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The frequency distributions for the first lines of treatment will be presented, as well as the rate distribution of the most frequent treatment sequences and their evolution. It will be reported the descriptive statistics period of the first treatment lines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the HRQOL evolution over time</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Descriptive statistics will be reported for each of the five dimensions at every period of application of the EQ-5D, so as an overall lineal model of repeated measures for the VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact on early mortality</measure>
    <time_frame>Up to approximately 8 weeks</time_frame>
    <description>The t-test will be used to evaluate the impact of the initial leukocyte count on early mortality (dichotomous variable minus death or not in the first 8 weeks). The stratified analysis with the same approach will be done for treatments that achieve a sufficient sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the prognostic impact on overall survival</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>A Cox regression model will be made considering the patient survival as a dependent variable and as possible factors the subjective variables (asthenia and HRQOL) at the time of diagnosis, the patient's general condition, and any other clinical variable that is evaluated as possible predictor. No more than 10 independent variables will be included in the model for theoretical reasons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the scales scores to be used as potential predictors tools of treatment tolerability in patients with newly diagnosed AML.</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The therapeutic approach will be collected according to the investigator clinical judgment, the score of each of the items on the Lee and GAH scales and the treatment administered tolerability assessment according to the score obtained in each scale. The weighting coefficients will be calculated using a complete multiple linear regression model and a multiple logistic regression. The optimal cut points for use as a predictive tool for treatment tolerability will be determined by using the ROC curve technique.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Patients diagnosed with AML</arm_group_label>
    <description>The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of approximately 150 patients over 60 with AML diagnosis,
        defined according to World Health Organization (WHO) 2016 criteria (presence of blasts in
        the bone marrow or peripheral blood equal to or greater than 20%).

        Due to the observational and descriptive nature of the present investigation, the inclusion
        of a control group is not considered.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of both sexes, aged 65 years and older.

          -  Any race, nationality or socioeconomic status.

          -  AML (defined according to WHO 2016 criteria de novo, with previous hematological
             history or secondary.

          -  Diagnosis date later than 1st November 2017 and later than each center activation
             date.

          -  Patients on first line treatment with any therapeutic strategy (intensive, attenuated
             or palliative).

          -  Having given informed consent prior to start the data collection.

        Exclusion Criteria:

          -  Inability to understand the informed consent form.

          -  AML previously treated (with or without HSCT).

          -  Acute promyelocytic leukemia.

          -  Participation in a clinical trial that includes first-line treatment for AML.

          -  Do not grant consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Montserrat Rafel, RML Advocacy</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez</city>
        <state>AndalucÃ­a/CÃ¡diz</state>
        <zip>AndalucÃ­a/CÃ¡diz</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <state>AndalucÃ­a/Granada</state>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>MÃ¡laga</city>
        <state>AndalucÃ­a/MÃ¡laga</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>AndalucÃ­a/Sevilla</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra SeÃ±ora de Valme</name>
      <address>
        <city>Sevilla</city>
        <state>AndalucÃ­a/Sevilla</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Reina Sofia</name>
      <address>
        <city>CÃ³rdoba</city>
        <state>AndalucÃ­a</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <state>AndalucÃ­a</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>AragÃ³n</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Castilla-La Mancha</state>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <state>Castilla-LeÃ³n</state>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de LeÃ³n</name>
      <address>
        <city>LeÃ³n</city>
        <state>Castilla-LeÃ³n</state>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla-LeÃ³n</state>
        <zip>37120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClÃ­nico de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <state>Castilla-LeÃ³n</state>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Granollers</name>
      <address>
        <city>Granollers, Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova Lleida</name>
      <address>
        <city>Lleida</city>
        <state>CataluÃ±a</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Althaia (H. Sant Juan de Deu de Manresa)</name>
      <address>
        <city>Manresa, Barcelona</city>
        <state>CataluÃ±a</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <state>Extremadura</state>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de A CoruÃ±a</name>
      <address>
        <city>La CoruÃ±a</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Orense</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. NegrÃ­n</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Islas Canarias</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra SeÃ±ora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa LucÃ­a</name>
      <address>
        <city>Cartagena, Murcia</city>
        <state>Murcia</state>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona, Navarra</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao, Vizcaya</city>
        <state>PaÃ­s Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San SebastiÃ¡n, GuipÃºzcoa</city>
        <state>PaÃ­s Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <state>PaÃ­s Vasco</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario RamÃ³n y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³n JimÃ©nez DÃ­az</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Getafe</name>
      <address>
        <city>Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>Observational</keyword>
  <keyword>Standard Clinical Practice</keyword>
  <keyword>Survival</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Spain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

